Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose to $37.89 per share in the last trading day compared to a prior close of $31.26. The management team hold 0.4 percent of the stock. Barry Richard ranks as top insider in Sarepta Therapeutics, Inc., noted in the Company’s filings with the U.S. Securities and Exchange Commission. The insider’s stake of 3,241,014 shares is worth $123,000,000. Behrens M Kathleen is ranked No.2 with 112,166 shares as of Mar 16, 2016, which sits at a market value around $4,249,970. Kaye Edward M. Md is another big name in this category. This insider owns 72,635 SRPT shares, amounting to about $2,752,140 as of recent trading price which is 10.09% above its 20-day moving average and 29.08% above its 50-day moving average. The equity dropped -34.28% over the trailing 3 months.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on January 10, 2017 announced that it has entered an exclusive license agreement with Nationwide Children’s Hospital, for their Galgt2 gene therapy program developed by researcher Dr. Paul Martin, Ph.D.

The experimental program explores the potential surrogate gene therapy approach to Duchenne muscular dystrophy. As a “surrogate gene therapy approach”, the gene therapy looks to induce genes that make proteins that can perform a similar function as dystrophin, with the goal of producing a muscle cell that can function normally even when dystrophin is absent. It has the potential to be used broadly in several muscular dystrophies.

Illumina, Inc. (NASDAQ:ILMN) shares closed at $165.04, up 23.5 points or 16.6 percent from  the previous close price. The up to date insider trading filings show Director BRADBURY DANIEL has disposed of 600 shares,reducing the ownership to 16,465 units. The transaction occurred on Jan 04, 2017, at $135.01 per share worth a total $81,010. There was another major transaction on the insider-trading front. OSTADAN OMEAD, EVP Ops, Products, Strategy at ILMN bought 2,000 common shares at a per share price of $126.16 to hold 31,040 shares. The stock recently traded at a volume of 0 shares vs. an average volume of 1.6M. The latest closing price is now lower -10.72% for the past quarter. The price is now 24.65% above its 50-day moving average and 10.34% above its 200-day moving average. The percentage change return over the last fifty two weeks remained -0.4%. The price range in the same period had a highest hit of $186.88 while lowest level in that period was $119.37.

On January 9, 2017, Illumina, Inc. (NASDAQ:ILMN) and Bio-Rad Laboratories, Inc. (BIO) (NYSE:BIO-B) announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.

Single-cell analysis enables a deep view into the gene expression of individual cells to understand their functions in complex tissues. The solution delivers high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly, and time consuming process. Human development and disease research, fields in which single-cell sequencing is widely applicable, is expected to benefit most from this new offering.

The solution comprises the ddSEQ™ Single-Cell Isolator and SureCell™ WTA 3’ Library Prep Kit. Bio-Rad’s best-in-class droplet partitioning technology, Droplet Digital™ technology, is used to isolate and barcode single cells for downstream sequencing on many of Illumina’s leading NGS instruments. The comprehensive workflow solution includes primary and secondary data analysis conducted via the BaseSpace® Informatics Suite, Illumina’s cloud-based genomics computing environment, and tertiary data analysis and visualization with SeqGeq™ from FlowJo, LLC, the market leader in flow cytometry analysis.